| All news about SIGILON THERAPEUTICS, INC. |
|
| 11:50a |
Canaccord Genuity Initiates Coverage on Sigilon Therapeutics With Buy Rating, $6 Price .. |
MT
|
| 2022 |
Sigilon Therapeutics, Inc. : Notice of Delisting or Failure to Satisfy a Continued Listing.. |
AQ
|
| 2022 |
SIGILON THERAPEUTICS, INC. Management’s Discussion and Analysis of Financial Condition.. |
AQ
|
| 2022 |
Sigilon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mont.. |
CI
|
| 2022 |
Sigilon Therapeutics, Inc. : Results of Operations and Financial Condition, Regulation FD .. |
AQ
|
| 2022 |
Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highligh.. |
AQ
|
| 2022 |
Sigilon Therapeutics, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (.. |
AQ
|
| 2022 |
Sigilon Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K) |
AQ
|
| 2022 |
Sigilon Therapeutics, Inc. Announces Resignation of Brooke Story from Her Position as M.. |
CI
|
| 2022 |
Sigilon Therapeutics : REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND BUSINESS HIGHLIGH.. |
PU
|
|
|
|
| Analyst Recommendations on SIGILON THERAPEUTICS, INC. |
|
|
|
|
|
|
| Sales 2022 |
12,5 M
–
–
|
| Net income 2022 |
-51,1 M
–
–
|
| Net cash 2022 |
58,4 M
–
–
|
| P/E ratio 2022 |
-0,27x |
| Yield 2022 |
– |
|
| Capitalization |
13,4 M
13,4 M
–
|
| EV / Sales 2022 |
-3,59x |
| EV / Sales 2023 |
0,11x |
| Nbr of Employees |
66 |
| Free-Float |
86,7% |
|
| Chart SIGILON THERAPEUTICS, INC. |
|
Duration :
Period :
|
 |
|
|
Technical analysis trends SIGILON THERAPEUTICS, INC.
|
Short Term |
Mid-Term |
Long Term |
| Trends |
Bullish |
Bearish |
Bearish |
Income Statement Evolution
|
|
| Mean consensus |
OUTPERFORM |
| Number of Analysts |
4 |
| Last Close Price |
0,41 $ |
| Average target price |
2,88 $ |
| Spread / Average Target |
596% |
|
